1. Introduction {#sec1-diseases-06-00087}
===============

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the developed world, and can progress to cirrhosis and hepatocellular carcinoma \[[@B1-diseases-06-00087]\]. It is also the most common cause of elevated liver enzymes. Risk factors for NAFLD include obesity, diabetes mellitus, and hyperlipidemia. Obesity is also a significant risk factor for NAFLD, independent of hyperlipidemia, and weight loss has a beneficial effect on the prevention of hepatic fibrosis \[[@B2-diseases-06-00087]\]. Patients with NAFLD are predisposed to cardiovascular mortality with studies demonstrating up to a twofold increase in the risk of cardiovascular disease in this population \[[@B3-diseases-06-00087]\]. There are several hypotheses regarding the pathogenesis of NAFLD, which include insulin resistance, oxidative stress, and lipotoxicity ([Figure 1](#diseases-06-00087-f001){ref-type="fig"}). Hyperlipidemia is a significant risk factor for NAFLD and associated cardiovascular disease. The precise mechanism of action and the exact pathogenetic pathway on how hyperlipidemia increases the risk of NAFLD has not been elucidated, but may be related to an increased accumulation of lipids in the hepatocytes. Major sources of fatty acid delivery to hepatocytes include splanchnic lipolysis of visceral fat, lipogenesis, and the ingestion of fatty foods. Insulin resistance also downregulates low density lipoprotein (LDL)-receptor expression, leading to elevated levels of LDL. Multiple studies have shown the efficacy of lipid-lowering drugs in patients with NAFLD and its subset non-alcoholic steatohepatitis (NASH). The aim of this article is to review the medical literature on the utility of different anti-hyperlipidemic drugs in patients with NAFLD.

2. Lipid-Lowering Drugs {#sec2-diseases-06-00087}
=======================

2.1. Statins {#sec2dot1-diseases-06-00087}
------------

Statins are the most widely used lipid lowering drugs due to their known efficacy in reducing cardiovascular mortality in patients with coronary artery disease and diabetes mellitus. These beneficial effects are not only due to the cholesterol-lowering ability of statins, but also due to their anti-inflammatory, vasodilatory (statins are nitric oxide donor), vascular remodeling, and anti-fibrotic effects independent of cholesterol-lowering activity. As inflammatory mechanisms are involved in the pathogenesis of NAFLD/NASH, statins have shown promising results decreasing liver fibrosis in patients with NAFLD. Generally, statins have been shown to be safe and effective treatment options for the indication of dyslipidemia in the context of NAFLD with the exception of Child-Pugh B and C cirrhosis and in particular if the total bilirubin level is greater than 3 mg/dL \[[@B4-diseases-06-00087],[@B5-diseases-06-00087]\]. [Table 1](#diseases-06-00087-t001){ref-type="table"} summarizes the current studies evaluating the utility of different statins in NAFLD and NASH.

2.2. Simvastatin {#sec2dot2-diseases-06-00087}
----------------

Multiple studies have shown safety and efficacy results of simvastatin in patients with NAFLD and NASH. Abel et al. conducted a study on a small group of NAFLD patients and revealed that simvastatin at 20 mg/day for 6 months significantly decreased aspartate aminotransferase (AST), alanine aminotransferase (ALT), and LDL cholesterol levels in these patients \[[@B6-diseases-06-00087]\]. Liver histological evaluation was not done in this study. In another randomized controlled trial, simvastatin at 40 mg/day for 12 months was compared with a placebo, which significantly reduced LDL cholesterol levels \[[@B7-diseases-06-00087]\]. Although patient cholesterol levels were lowered in the simvastatin group, no significant differences were found in levels of transaminases or hepatic fibrosis.

2.3. Atorvastatin {#sec2dot3-diseases-06-00087}
-----------------

Several clinical studies reported the safety and efficacy of atorvastatin in NAFLD/NASH patients \[[@B8-diseases-06-00087],[@B9-diseases-06-00087],[@B10-diseases-06-00087],[@B11-diseases-06-00087],[@B12-diseases-06-00087]\]. A randomized controlled trial comparing atorvastatin with the combination of atorvastatin and fenofibrate or fenofibrate alone revealed that atorvastatin alone or in combination with fenofibrate could improve liver enzymes and ultrasonographic features of NAFLD \[[@B8-diseases-06-00087]\]. In a St. Francis Heart study, atorvastatin along with vitamins C and E was associated with reduced likelihood of developing hepatic steatosis in patients with NAFLD \[[@B9-diseases-06-00087]\]. Although the results of this study were promising, they may be confounded by the use of vitamin E, as vitamin E alone has been shown to be beneficial in NAFLD patients \[[@B19-diseases-06-00087]\]. In a study by Gomez-Dominguez, 22 hyperlipidemic NAFLD patients received 10--80 mg/day of atorvastatin for 6 months and showed significant improvement in aminotransferase and cholesterol levels \[[@B10-diseases-06-00087]\]. Kimura et al. reported the role of advanced glycation end products (AGEs) in NASH, as the levels of these products were significantly high in NASH patients. Treatment of patients with atorvastatin resulted in a significant decrease in AGE levels and an improvement in metabolic parameters related to NASH \[[@B11-diseases-06-00087]\]. In a study done on 27 biopsy-proven NASH patients with hyperlipidemia, Kiyci et al. revealed the promising effects of atorvastatin 10 mg/day for 6 months \[[@B12-diseases-06-00087]\]. Atorvastatin was shown to decrease aminotransferase activity and significantly decrease fatty infiltration of the liver. These studies favor the beneficial effects of atorvastatin in NAFLD patients.

2.4. Pravastatin {#sec2dot4-diseases-06-00087}
----------------

The current evidence regarding the use of pravastatin in NAFLD patients is lacking. In a study on five patients with biopsy-proven steatohepatitis, Rallidis et al. revealed that the use of pravastatin resulted in an improvement of hepatic histological findings \[[@B13-diseases-06-00087]\]. Further studies---especially randomized controlled trials---are needed to further investigate the utility of pravastatin in NAFLD patients.

2.5. Pitavastatin {#sec2dot5-diseases-06-00087}
-----------------

Pitavastatin has been indicated to be beneficial in inhibiting hepatic fibrosis in NASH rat models, but research on its utility in patients with NAFLD is still too premature to make any conclusions. Hyogo et al. conducted an open-label pilot study that revealed 2 mg/day of pitavastatin for 12 months decreased the severity of hepatic steatosis and NASH-related parameters \[[@B14-diseases-06-00087]\]. Although the study results are promising, further studies are necessary to support these findings.

2.6. Lovastatin {#sec2dot6-diseases-06-00087}
---------------

In a multicentric prospective study, 10 mg/day of lovastatin for four months was shown to significantly decrease transaminases, cholesterol levels, and aminotransferase to platelet ratio indices \[[@B15-diseases-06-00087]\]. Again, more studies are needed to support the beneficial effects of lovastatin in NAFLD patients.

2.7. Rosuvastatin {#sec2dot7-diseases-06-00087}
-----------------

In a preliminary report on six patients with NASH, 10 mg/day of rosuvastatin for 12 months not only showed improvement in AST and ALT levels, but also the complete resolution of ultrasonographic findings of NASH in five patients \[[@B16-diseases-06-00087]\]. Similar beneficial effects were seen in a prospective study on 20 patients, in which 10 mg/day of rosuvastatin for 12 months resulted in the complete resolution of ultrasonographic findings of NASH in 19 patients \[[@B17-diseases-06-00087]\]. Nakahara et al. also revealed beneficial effects of 2.5 mg/day of rosuvastatin for 24 months, and showed an improvement of NASH-related parameters and histological features in some patients \[[@B18-diseases-06-00087]\].

2.8. Non-Statin Lipid Lowering Drugs {#sec2dot8-diseases-06-00087}
------------------------------------

[Table 2](#diseases-06-00087-t002){ref-type="table"} summarizes the current evidence regarding the utility of lipid-lowering drugs other than statins in patients with NAFLD and NASH.

2.9. Fibrates {#sec2dot9-diseases-06-00087}
-------------

Fibrates or fibric acid derivatives are used to treat hypertriglyceridemia and primary hypercholesterolemia, mainly by activating peroxisome proliferator-activated receptor alpha (PPAR-alpha). Multiple studies have been done to evaluate the safety and efficacy of these agents in treating hyperlipidemia in NAFLD/NASH patients \[[@B8-diseases-06-00087],[@B20-diseases-06-00087],[@B21-diseases-06-00087],[@B22-diseases-06-00087]\]. In a prospective open-label randomized study, Athyros et al. included 186 patients that were randomly assigned to receive either 20 mg/day of atorvastatin, 200 mg/day of fenofibrate, or both \[[@B8-diseases-06-00087]\]. A complete resolution of biochemical and ultrasonographic evidence of NAFLD was seen in 42% of the patients in the fenofibrate group compared to 67% of patients taking atorvastatin alone, and 70% in the combination therapy group \[[@B8-diseases-06-00087]\]. In a randomized controlled trial (RCT), Basarangolu et al. included 23 patients taking 600 mg/day of gemfibrozil for four weeks, and compared these with 23 placebo patients who were not treated with any lipid-lowering drugs. Patients in the gemfibrozil group had significantly lower levels of AST, ALT, and GGT without any significant changes in liver histology \[[@B20-diseases-06-00087]\]. Laurin et al. evaluated the utility of the fibric acid derivative clofibrate in 16 NASH patients with hyperlipidemia taking 2 g /day \[[@B21-diseases-06-00087]\]. The study did not find any improvement in aminotransferases, GGT, or bilirubin levels. In a pilot study on 16 biopsy-proven NAFLD patients, Fernandez-Miranda et al. revealed that 200 mg/day of fenofibrate for 48 weeks resulted in decreased insulin resistance, aminotransferases levels, and signs of metabolic syndrome \[[@B22-diseases-06-00087]\]. Although the drug showed promising results in decreasing the proportion of patients with metabolic syndrome, its effect on liver histology was minimal. Hence, considering current evidence, we conclude that the utility of fibrates and fibric acid derivatives in ameliorating the histological features of NAFLD is still unclear and requires further studies.

2.10. Elafibranor {#sec2dot10-diseases-06-00087}
-----------------

Elafibranor is an activator of both Peroxisome proliferator-activated receptor (PPAR)-α and PPAR-δ that has anti-inflammatory effects and helps to improve lipid metabolism and insulin resistance. In a randomized controlled double-blind trial, 276 patients with NASH were divided into three groups to receive either 80 mg/day of elafibranor, 120 mg/day of elafibranor, or a placebo for 52 weeks \[[@B23-diseases-06-00087]\]. Aminotransferase activity, glucose levels, and inflammatory markers were significantly lower in the elafibranor 120 mg group compared to the placebo group. A post-hoc analysis of the study also revealed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening in the greater proportion of patients compared to placebo, but there was no difference in the outcome in the intention-to-treat analysis \[[@B23-diseases-06-00087]\]. These results are encouraging for the use of elafibranor in NASH patients, but require further studies---especially randomized controlled trials---to further strengthen the evidence of these beneficial effects.

2.11. Niacin {#sec2dot11-diseases-06-00087}
------------

Niacin (nicotinic acid or vitamin B-3) is used to treat vitamin deficiency (pellagra) and has lipid-lowering effects. The mechanism by which these drugs exert their lipid-lowering effects is still unclear. Fabbrini et al. reported that the combination of 200 mg/day of fenofibrate for 8 weeks and extended-release niacin at 2000 mg/day for 16 weeks lowered the plasma levels of VLDL-triglycerides, but did not alter intrahepatic triglyceride content \[[@B24-diseases-06-00087]\]. The safety and efficacy of niacin in NAFLD patients has yet to be established, and requires further clinical studies.

2.12. Ezetimibe {#sec2dot12-diseases-06-00087}
---------------

Ezetimibe exerts its lipid-lowering effects by inhibiting small intestinal absorption of cholesterol via its effects on the sterol transporter Niemann--Pick C1-Like1 (NPC1L1). These molecules are also expressed in the liver, and play a role in hepatic cholesterol accumulation. The combination of ezetimibe and statins has been shown to improve LDL cholesterol levels in patients with hypercholesterolemia. In one study, Yoneda et al. reported 10 mg/day of ezetimibe for 6 months in NASH patients with hyperlipidemia resulted in significant improvement in histological findings, NAFLD activity scores, and steatosis in the liver \[[@B25-diseases-06-00087]\]. They also revealed improvement in AST, ALT, GGT, LDL cholesterol levels, and C-reactive protein (CRP) in these patients. Similar results were seen in a study done by Park et al. regarding 45 patients with biopsy-proven NAFLD \[[@B26-diseases-06-00087]\]. They reported that 10 mg/day of ezetimibe for 24 months improved the biochemical and histological abnormalities of NAFLD. Chan et al. also reported that weight loss along with ezetimibe was associated with an improvement in hepatic steatosis \[[@B27-diseases-06-00087]\]. These study results favor the use of ezetimibe in NAFLD/NASH patients with hyperlipidemia, as it might ameliorate the biochemical and histological features of NAFLD.

2.13. Omega-3 (n-3) Polyunsaturated Fatty Acids (PUFAs) {#sec2dot13-diseases-06-00087}
-------------------------------------------------------

The use of n-3 PUFAs increases the levels of adiponectin in the blood and decreases serum levels of triglycerides, leptin, and insulin, which promote weight loss and improve insulin resistance \[[@B28-diseases-06-00087],[@B29-diseases-06-00087]\]. In a study of 40 patients with NAFLD, Spadro et al. reported improvement in serum AST, ALT, triglyceride levels, and fatty liver with the use of n-3 PUFAs \[[@B28-diseases-06-00087]\]. Similar beneficial effects were seen in a study by Capanni et al., which reported that n-3 PUFA supplementation of 1 g/day for 12 months resulted in the improvement of AST, ALT, GGT, triglycerides, and ultrasonographic features of hepatic steatosis \[[@B29-diseases-06-00087]\]. Current evidence is therefore encouraging, but further studies are needed to define the utility of n-3 PUFAs for management of NAFLD.

3. Conclusions {#sec3-diseases-06-00087}
==============

Statins have been shown to be most beneficial in the prevention of hepatic fibrosis in patients with NAFLD/NASH. Hence, in light of current evidence, we recommend considering statins and vitamin E along with weight loss and exercise in these patients. Although evidence regarding the utility of lipid-lowering drugs in patients with NAFLD/NASH is convincing, with most studies reporting that lipid-lowering drug use showed an improvement in hepatic steatosis, formal guidelines are lacking in this regard---mainly due to the absence of larger randomized controlled trials. Despite the need for more randomized controlled trials regarding these drugs, our review will help guide clinicians in prescribing lipid-lowering agents in NAFLD patients. This, in turn, may help decrease the morbidity and mortality associated with this serious disease.

Writing-Original Draft Preparation, U.I., B.J.P., G.C., N.J., S.S., N.D.S., W.K., A.A.; Writing-Review & Editing, D.K., A.A.; Supervision, A.A.

There were no funding sources for this study.

The authors declare no conflicts of interest, including financial and/or material support for the preparation of this manuscript.

![Pathogenesis of NAFLD/NASH and potential targets for treatment. HCC (Hepatocellular carcinoma).](diseases-06-00087-g001){#diseases-06-00087-f001}

diseases-06-00087-t001_Table 1

###### 

Studies evaluating the utility of Statins in non-alcoholic fatty liver disease (NAFLD)/ non-alcoholic steatohepatitis (NASH).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author's Name and Year of Publication                  Drug(s) Used                      Dose                                                            Patient Population and Sample Size                                        Duration of Therapy        Outcome
  ------------------------------------------------------ --------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Abel et al. \[[@B6-diseases-06-00087]\]\               Simvastatin                       20 mg/day                                                       45 patients with NAFLD secondary to diabetes and metabolic syndrome       6 months                   Decrease in aspartate aminotransferase (AST), and alanine aminotransferase (ALT) and low density lipoprotein (LDL) cholesterol. Liver histology was not evaluated.
  2009                                                                                                                                                                                                                                                          

  Nelson et al. \[[@B7-diseases-06-00087]\]\             Simvastatin                       40 mg/day                                                       16 patients with biopsy-proven NASH                                       12 months                  No significant difference from the improvement of transaminases or hepatic fibrosis. A 26% reduction in LDL levels was seen in the simvastatin group.
  2009                                                                                                                                                                                                                                                          

  Athyros et al. \[[@B8-diseases-06-00087]\]\            Atorvastatin and/or Fenofibrate   20 mg/day alone or in combination with fenofibrate 200 mg/day   186 non-diabetic patients with NAFLD and metabolic syndrome               54 weeks                   67% of patients on atorvastatin, 42% on fenofibrate, and 70% on combination treatment no longer had biochemical and ultrasonographic evidence of NAFLD.
  2006                                                                                                                                                                                                                                                          

  Foster et al. \[[@B9-diseases-06-00087]\]\             Atorvastatin                      20 mg/day along with vitamin C 1g, and vitamin E 1000 IU        1005 healthy men and women between ages 50--70                            Mean follow-up 3.6 years   Reduced odds of having hepatic steatosis in NAFLD patients by 71%.
  2011                                                                                                                                                                                                                                                          

  Gómez-Domínguez et al. \[[@B10-diseases-06-00087]\]\   Atorvastatin                      10--80 mg/day                                                   25 patients with NAFLD (only 22 completed the study)                      6 months                   Significant improvement in aminotransferase activities and cholesterol levels.
  2006                                                                                                                                                                                                                                                          

  Kimura et al. \[[@B11-diseases-06-00087]\]\            Atorvastatin                      10 mg/day                                                       43 NASH patients with dyslipidemia                                        12 months                  Improvement in metabolic parameters related to NASH.
  2010                                                                                                                                                                                                                                                          

  Kiyci et al. \[[@B12-diseases-06-00087]\]\             Atorvastatin                      10 mg/day                                                       44 patients with NASH                                                     6 months                   Decrease in aminotransferase activity and fatty infiltration of the liver.
  2003                                                                                                                                                                                                                                                          

  Rallidis et al. \[[@B13-diseases-06-00087]\]\          Pravastatin                       20 mg/day                                                       5 patients with steatohepatitis and liver enzyme abnormalities            6 months                   Improvement in histologic findings of steatohepatitis.
  2004                                                                                                                                                                                                                                                          

  Hyogo et al. \[[@B14-diseases-06-00087]\]\             Pitavastatin                      2 mg/day                                                        20 NASH patients with dyslipidemia                                        12 months                  Decrease in severity of hepatic steatosis. Fibrosis stage improved in 42% of the patients.
  2011                                                                                                                                                                                                                                                          

  Mihaila et al. \[[@B15-diseases-06-00087]\]\           Lovastatin                        10 mg/day                                                       87 patients with NASH and dyslipidemia                                    4 months                   Decrease in aminotransferase and cholesterol levels.
  2009                                                                                                                                                                                                                                                          

  Kargiotis et al. \[[@B16-diseases-06-00087]\]\         Rosuvastatin                      10 mg/day                                                       6 non-diabetic patients with NASH, metabolic syndrome, and dyslipidemia   12 months                  Resolution of ultrasonographic findings of NASH. Improvement in aminotransferases; ALT and AST levels were reduced by 76% and 61%, respectively.
  2014                                                                                                                                                                                                                                                          

  Kargiotis et al. \[[@B17-diseases-06-00087]\]\         Rosuvastatin                      10 mg/day                                                       20 patients with NASH, metabolic syndrome, and dyslipidemia               12 months                  Resolution of ultrasonographic findings of NASH.
  2015                                                                                                                                                                                                                                                          

  Nakahara et al. \[[@B18-diseases-06-00087]\]\          Rosuvastatin                      2.5 mg/day                                                      19 patients with NASH and dyslipidemia                                    24 months                  Improvement of NASH-related parameters, with 33.3% patients showing improvement in non-alcoholic fatty liver disease activity score and fibrotic stage.
  2012                                                                                                                                                                                                                                                          
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

diseases-06-00087-t002_Table 2

###### 

Studies evaluating the utility of lipid-lowering drugs in NAFLD/NASH.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author's Name and Year of Publication                    Drug(s) Used                                            Dose                                                             Patient Population and Sample Size                            Duration of Therapy   Outcome
  -------------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------------- --------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Athyros et al. \[[@B8-diseases-06-00087]\]\              Fenofibrate alone or in combination with atorvastatin   200 mg/day alone or in combination with atorvastatin 20 mg/day   186 non-diabetic patients with NAFLD and metabolic syndrome   54 weeks              42% of the patients in the fenofibrate-only treatment group had a complete resolution of biochemical and ultrasonographic evidence of NAFLD.
  2006                                                                                                                                                                                                                                                                  

  Basarangolu et al. \[[@B20-diseases-06-00087]\]\         Gemfibrozil                                             600 mg/day                                                       46 patients with NASH and liver enzyme abnormalities          4 weeks               Lower levels of ALT, AST, and gamma glutamyl transferase (GGT). No change in liver histology.
  1999                                                                                                                                                                                                                                                                  

  Laurin et al. \[[@B21-diseases-06-00087]\]\              Clofibrate                                              2 g/day                                                          40 patients with NASH                                         12 months             No improvement in aminotransferase activities.
  1996                                                                                                                                                                                                                                                                  

  Fernandez-Miranda et al. \[[@B22-diseases-06-00087]\]\   Fenofibrate                                             200 mg/day                                                       16 NAFLD patients                                             48 weeks              Decrease in insulin resistance, aminotransferases levels, and signs of metabolic syndrome. No significant effect on liver histology.
  2008                                                                                                                                                                                                                                                                  

  Ratziu et al. \[[@B23-diseases-06-00087]\]\              Elafibranor                                             120 mg/day                                                       276 patients with NASH without cirrhosis                      52 weeks              Resolution of NASH without fibrosis worsening in the greater proportion of patients compared to placebo (19% vs. 12%; odds ratio = 2.31; *p* = 0.045).
  2016                                                                                                                                                                                                                                                                  

  Fabbrini et al. \[[@B24-diseases-06-00087]\]\            Niacin                                                  2000 mg/day                                                      27 obese patients with NAFLD                                  16 weeks              Lowered plasma levels of very-low density lipoprotein (VLDL)-TGs but no change in intrahepatic triglycerides (TGs) content.
  2010                                                                                                                                                                                                                                                                  

  Yoneda et al. \[[@B25-diseases-06-00087]\]\              Ezetimibe                                               10 mg/day                                                        10 patients with NASH and dyslipidemia                        6 months              Improvement in hepatic steatosis and histological findings. 6 out of 10 patients showed improvement in their fibrosis stage.
  2010                                                                                                                                                                                                                                                                  

  Park et al. \[[@B26-diseases-06-00087]\]\                Ezetimibe                                               10 mg/day                                                        45 NAFLD patients                                             24 months             Improvement in biochemical and histological abnormalities of NAFLD.
  2011                                                                                                                                                                                                                                                                  

  Chan et al. \[[@B27-diseases-06-00087]\]\                Ezetimibe                                               10 mg/day                                                        25 patients with central obesity                              16 weeks              Improvement in hepatic steatosis.
  2010                                                                                                                                                                                                                                                                  

  Spadro et al. \[[@B28-diseases-06-00087]\]\              Omega-3 (n-3) polyunsaturated fatty acids (PUFAs)       2 g/day                                                          40 patients with NAFLD                                        6 months              Improvement in serum AST, ALT, triglyceride levels, and fatty liver.
  2008                                                                                                                                                                                                                                                                  

  Capanni et al. \[[@B29-diseases-06-00087]\]\             n-3 PUFAs                                               1 g/day                                                          56 patients with NAFLD                                        12 months             Improvement of AST, ALT, GGT, triglycerides, and ultrasonographic features of hepatic steatosis.
  2006                                                                                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
